Skip Nav Destination
Issues
Effects of oral hypoglycemic agents and diet on protein metabolism in type 2 diabetes.
Diabetes Care January 2000, Vol.23, 1-8. doi:https://doi.org/10.2337/diacare.23.1.1
Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial.
V Vuksan; J L Sievenpiper; R Owen; J A Swilley; P Spadafora; D J Jenkins; E Vidgen; F Brighenti; R G Josse; L A Leiter; Z Xu; R Novokmet
Diabetes Care January 2000, Vol.23, 9-14. doi:https://doi.org/10.2337/diacare.23.1.9
Gestational diabetes: is a higher cesarean section rate inevitable?
Diabetes Care January 2000, Vol.23, 15-17. doi:https://doi.org/10.2337/diacare.23.1.15
Alcohol intake and incidence of type 2 diabetes in men.
Diabetes Care January 2000, Vol.23, 18-22. doi:https://doi.org/10.2337/diacare.23.1.18
Depressive symptoms and metabolic control in African-Americans with type 2 diabetes.
Diabetes Care January 2000, Vol.23, 23-29. doi:https://doi.org/10.2337/diacare.23.1.23
Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy.
Diabetes Care January 2000, Vol.23, 30-33. doi:https://doi.org/10.2337/diacare.23.1.30
Impaired fasting glucose: how low should it go?
Diabetes Care January 2000, Vol.23, 34-39. doi:https://doi.org/10.2337/diacare.23.1.34
Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study.
Diabetes Care January 2000, Vol.23, 45-50. doi:https://doi.org/10.2337/diacare.23.1.45
Trends in persistent proteinuria in adult-onset diabetes: a population-based study.
Diabetes Care January 2000, Vol.23, 51-56. doi:https://doi.org/10.2337/diacare.23.1.51
Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Diabetes Care January 2000, Vol.23, 64-69. doi:https://doi.org/10.2337/diacare.23.1.64
Sulfonylurea receptor 1 gene variants are associated with gestational diabetes and type 2 diabetes but not with altered secretion of insulin.
J Rissanen; A Markkanen; P Kärkkäinen; J Pihlajamäki; P Kekäläinen; L Mykkänen; J Kuusisto; P Karhapää; L Niskanen; M Laakso
Diabetes Care January 2000, Vol.23, 70-73. doi:https://doi.org/10.2337/diacare.23.1.70
Association of hyperandrogenemia and hyperestrogenemia with type 2 diabetes in Hispanic postmenopausal women.
Diabetes Care January 2000, Vol.23, 74-79. doi:https://doi.org/10.2337/diacare.23.1.74
Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study.
Diabetes Care January 2000, Vol.23, 80-83. doi:https://doi.org/10.2337/diacare.23.1.80
Total homocysteine in patients with type 1 diabetes.
Diabetes Care January 2000, Vol.23, 84-87. doi:https://doi.org/10.2337/diacare.23.1.84
Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
Diabetes Care January 2000, Vol.23, 88-92. doi:https://doi.org/10.2337/diacare.23.1.88
Immunization and the prevention of influenza and pneumococcal disease in people with diabetes: American Diabetes Association.
Diabetes Care January 2000, Vol.23, 109-111. doi:https://doi.org/10.2337/diacare.23.1.109
Pancreas and islet transplantation for patients with diabetes.
Diabetes Care January 2000, Vol.23, 112-116. doi:https://doi.org/10.2337/diacare.23.1.112
Diabetes screening practices among individuals aged 45 years and older.
Diabetes Care January 2000, Vol.23, 125-126. doi:https://doi.org/10.2337/diacare.23.1.125
Pro115Gln peroxisome proliferator-activated receptor-gamma and obesity.
Diabetes Care January 2000, Vol.23, 126-127. doi:https://doi.org/10.2337/diacare.23.1.126a
HbA1c is not recommended as a screening test for diabetes in cystic fibrosis.
Diabetes Care January 2000, Vol.23, 126. doi:https://doi.org/10.2337/diacare.23.1.126b
Insulin secretion, insulin sensitivity, and glucose effectiveness in nonobese individuals with varying degrees of glucose tolerance.
Diabetes Care January 2000, Vol.23, 127-128. doi:https://doi.org/10.2337/diacare.23.1.127
Late-onset troglitazone-induced hepatic dysfunction.
Diabetes Care January 2000, Vol.23, 128-129. doi:https://doi.org/10.2337/diacare.23.1.128
Effects of exposure at an altitude of 3,000 m on performance of glucose meters.
Diabetes Care January 2000, Vol.23, 129-131. doi:https://doi.org/10.2337/diacare.23.1.129a
Deterioration of glycemic control after long-term treatment with troglitazone in nonobese type 2 diabetic patients.
Diabetes Care January 2000, Vol.23, 131-132. doi:https://doi.org/10.2337/diacare.23.1.131
